SI2528897T1 - Disubstituirani derivati piridina kot protitumorne uäśinkovine - Google Patents

Disubstituirani derivati piridina kot protitumorne uäśinkovine

Info

Publication number
SI2528897T1
SI2528897T1 SI201130359T SI201130359T SI2528897T1 SI 2528897 T1 SI2528897 T1 SI 2528897T1 SI 201130359 T SI201130359 T SI 201130359T SI 201130359 T SI201130359 T SI 201130359T SI 2528897 T1 SI2528897 T1 SI 2528897T1
Authority
SI
Slovenia
Prior art keywords
anticancers
pyridine derivatives
substituted pyridine
substituted
derivatives
Prior art date
Application number
SI201130359T
Other languages
English (en)
Inventor
Hideki Takasu
Shigekazu Fujita
Shinya Ohtsuka
Toshiyuki Hirose
Yosuke Sato
Satoshi Yamada
Keisuke Miyajima
Koji Sakai
Yutaka Kojima
Kazuo Sekiguchi
Yasuo Yanagihara
Takashi Suzuki
Hideo Tanaka
Kazuhisa Sugiyama
Mitsuhiro Okuno
Takumi Sumida
Original Assignee
Otsuka Pharmaceutical Co., Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co., Ltd. filed Critical Otsuka Pharmaceutical Co., Ltd.
Publication of SI2528897T1 publication Critical patent/SI2528897T1/sl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/69Two or more oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
SI201130359T 2010-01-29 2011-01-28 Disubstituirani derivati piridina kot protitumorne uäśinkovine SI2528897T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US29963110P 2010-01-29 2010-01-29
US35972910P 2010-06-29 2010-06-29
PCT/JP2011/052302 WO2011093524A1 (en) 2010-01-29 2011-01-28 Di - substituted pyridine derivatives as anticancers
EP11705048.4A EP2528897B9 (en) 2010-01-29 2011-01-28 Di-substituted pyridine derivatives as anticancers

Publications (1)

Publication Number Publication Date
SI2528897T1 true SI2528897T1 (sl) 2015-02-27

Family

ID=43797869

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201130359T SI2528897T1 (sl) 2010-01-29 2011-01-28 Disubstituirani derivati piridina kot protitumorne uäśinkovine

Country Status (27)

Country Link
US (1) US8722663B2 (sl)
EP (1) EP2528897B9 (sl)
JP (1) JP5335932B2 (sl)
KR (1) KR101411030B1 (sl)
CN (1) CN102791690B (sl)
AR (1) AR080057A1 (sl)
AU (1) AU2011211306B2 (sl)
CA (1) CA2788073A1 (sl)
CO (1) CO6561817A2 (sl)
DK (1) DK2528897T3 (sl)
EA (1) EA026042B1 (sl)
ES (1) ES2521016T3 (sl)
HK (1) HK1178523A1 (sl)
HR (1) HRP20141190T1 (sl)
IL (1) IL221146A (sl)
MX (1) MX2012008391A (sl)
MY (1) MY160875A (sl)
NZ (1) NZ601794A (sl)
PL (1) PL2528897T3 (sl)
PT (1) PT2528897E (sl)
RS (1) RS53705B1 (sl)
SG (1) SG182663A1 (sl)
SI (1) SI2528897T1 (sl)
SM (1) SMT201500007B (sl)
TW (1) TWI404713B (sl)
UA (1) UA107692C2 (sl)
WO (1) WO2011093524A1 (sl)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013047223A (ja) * 2011-07-28 2013-03-07 Otsuka Pharmaceut Co Ltd 医薬
CA2905993C (en) 2013-03-14 2022-12-06 Tolero Pharmaceuticals, Inc. Substituted 4-amino-pyrimidinyl-2-amino-phenyl derivatives and pharmaceutical compositions thereof for use as jak2 and alk2 inhibitors
US9227978B2 (en) 2013-03-15 2016-01-05 Araxes Pharma Llc Covalent inhibitors of Kras G12C
WO2014143659A1 (en) 2013-03-15 2014-09-18 Araxes Pharma Llc Irreversible covalent inhibitors of the gtpase k-ras g12c
EP3816155A1 (en) * 2013-08-23 2021-05-05 Virginia Commonwealth University Ester nitrates derivatives of aromatic aldehydes with multiple pharmalogic properties to treat sickle cell disease
TWI659021B (zh) 2013-10-10 2019-05-11 亞瑞克西斯製藥公司 Kras g12c之抑制劑
JO3556B1 (ar) 2014-09-18 2020-07-05 Araxes Pharma Llc علاجات مدمجة لمعالجة السرطان
US10011600B2 (en) 2014-09-25 2018-07-03 Araxes Pharma Llc Methods and compositions for inhibition of Ras
US9862701B2 (en) 2014-09-25 2018-01-09 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
KR20180005178A (ko) 2015-04-10 2018-01-15 아락세스 파마 엘엘씨 치환된 퀴나졸린 화합물 및 이의 사용방법
WO2016168540A1 (en) 2015-04-15 2016-10-20 Araxes Pharma Llc Fused-tricyclic inhibitors of kras and methods of use thereof
US10144724B2 (en) 2015-07-22 2018-12-04 Araxes Pharma Llc Substituted quinazoline compounds and methods of use thereof
US10882847B2 (en) 2015-09-28 2021-01-05 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
EP3356353A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10730867B2 (en) 2015-09-28 2020-08-04 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10689356B2 (en) 2015-09-28 2020-06-23 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017058768A1 (en) 2015-09-28 2017-04-06 Araxes Pharma Llc Inhibitors of kras g12c mutant proteins
EP3356349A1 (en) 2015-09-28 2018-08-08 Araxes Pharma LLC Inhibitors of kras g12c mutant proteins
US10875842B2 (en) 2015-09-28 2020-12-29 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
WO2017070256A2 (en) 2015-10-19 2017-04-27 Araxes Pharma Llc Method for screening inhibitors of ras
TW201726656A (zh) 2015-11-16 2017-08-01 亞瑞克西斯製藥公司 包含經取代雜環基團之2-經取代喹唑啉化合物及其使用方法
WO2017100546A1 (en) 2015-12-09 2017-06-15 Araxes Pharma Llc Methods for preparation of quinazoline derivatives
US10822312B2 (en) 2016-03-30 2020-11-03 Araxes Pharma Llc Substituted quinazoline compounds and methods of use
US10646488B2 (en) 2016-07-13 2020-05-12 Araxes Pharma Llc Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
US10280172B2 (en) 2016-09-29 2019-05-07 Araxes Pharma Llc Inhibitors of KRAS G12C mutant proteins
US10377743B2 (en) 2016-10-07 2019-08-13 Araxes Pharma Llc Inhibitors of RAS and methods of use thereof
JP7327802B2 (ja) 2017-01-26 2023-08-16 アラクセス ファーマ エルエルシー 縮合ヘテロ-ヘテロ二環式化合物およびその使用方法
EP3573970A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer
EP3573954A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC Fused bicyclic benzoheteroaromatic compounds and methods of use thereof
US11358959B2 (en) 2017-01-26 2022-06-14 Araxes Pharma Llc Benzothiophene and benzothiazole compounds and methods of use thereof
EP3573971A1 (en) 2017-01-26 2019-12-04 Araxes Pharma LLC 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1yl)prop-2-en-1-one derivatives and similar compounds as kras g12c modulators for treating cancer
WO2018218071A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Compounds and methods of use thereof for treatment of cancer
AU2018271990A1 (en) 2017-05-25 2019-12-12 Araxes Pharma Llc Covalent inhibitors of KRAS
WO2018218069A1 (en) 2017-05-25 2018-11-29 Araxes Pharma Llc Quinazoline derivatives as modulators of mutant kras, hras or nras
US11013741B1 (en) 2018-04-05 2021-05-25 Sumitomo Dainippon Pharma Oncology, Inc. AXL kinase inhibitors and use of the same
CN112512597A (zh) 2018-07-26 2021-03-16 大日本住友制药肿瘤公司 用于治疗与acvr1表达异常相关的疾病的方法以及用于此的acvr1抑制剂
CN112812781B (zh) * 2021-01-21 2023-09-29 西安瑞联新材料股份有限公司 一种基于双哌嗪类苯并噁唑液晶化合物及其制备方法
CN116903587B (zh) * 2023-06-01 2024-03-22 三峡大学 一种角鲨烯环氧酶抑制剂及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63301880A (ja) * 1985-09-03 1988-12-08 Otsuka Pharmaceut Co Ltd 5−フルオロウラシル誘導体
AR015733A1 (es) * 1998-03-25 2001-05-16 Otsuka Pharma Co Ltd DERIVADO DE PIRIDINA, EL PRODUCTO Y LA COMPOSICIoN FARMACEUTICA QUE CONTIENE DICHO DERIVADO.
US6262088B1 (en) * 1998-11-19 2001-07-17 Berlex Laboratories, Inc. Polyhydroxylated monocyclic N-heterocyclic derivatives as anti-coagulants
JP2001089412A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ベンゼン誘導体またはその医薬的に許容される塩
JP2001089450A (ja) * 1999-09-22 2001-04-03 Otsuka Pharmaceut Co Ltd ピリジン誘導体含有医薬製剤
JP2002226429A (ja) * 2001-02-06 2002-08-14 Fuji Photo Film Co Ltd アクリル酸エステル化合物の製造方法
GB0224917D0 (en) * 2002-10-25 2002-12-04 Novartis Ag Organic compounds
AU2005268030B2 (en) * 2004-08-06 2009-02-19 Otsuka Pharmaceutical Co., Ltd. Aromatic compounds
PT1957073E (pt) 2005-12-05 2014-05-12 Otsuka Pharma Co Ltd Medicamento
JP5142513B2 (ja) * 2005-12-05 2013-02-13 大塚製薬株式会社 医薬
UA95978C2 (ru) * 2006-10-02 2011-09-26 Оцука Фармас'Ютікел Ко., Лтд. Ингибитор активации stat3/5
US20100136509A1 (en) 2007-07-02 2010-06-03 Alden Mejer System and method for clinical trial investigator meeting delivery and training including dynamic media enrichment
TWI440638B (zh) * 2007-10-30 2014-06-11 Otsuka Pharma Co Ltd 雜環化合物及其藥學組成物
DE202009007345U1 (de) 2009-05-22 2009-09-10 Schebo (R) . Biotech Ag Neue Pharmazeutika und Arzneimittelzubereitungen

Also Published As

Publication number Publication date
CN102791690B (zh) 2015-12-02
HK1178523A1 (en) 2013-09-13
TWI404713B (zh) 2013-08-11
TW201136912A (en) 2011-11-01
KR101411030B1 (ko) 2014-06-30
CA2788073A1 (en) 2011-08-04
NZ601794A (en) 2014-04-30
MX2012008391A (es) 2012-08-15
RS53705B1 (en) 2015-04-30
UA107692C2 (uk) 2015-02-10
SMT201500007B (it) 2015-03-05
EA201290720A1 (ru) 2013-02-28
HRP20141190T1 (hr) 2015-01-30
US8722663B2 (en) 2014-05-13
JP2012525324A (ja) 2012-10-22
ES2521016T3 (es) 2014-11-12
SG182663A1 (en) 2012-08-30
DK2528897T3 (en) 2014-12-08
PT2528897E (pt) 2014-11-12
JP5335932B2 (ja) 2013-11-06
WO2011093524A9 (en) 2011-12-01
EA026042B1 (ru) 2017-02-28
MY160875A (en) 2017-03-31
CO6561817A2 (es) 2012-11-15
EP2528897B9 (en) 2015-09-09
US20120283242A1 (en) 2012-11-08
AR080057A1 (es) 2012-03-07
AU2011211306B2 (en) 2016-07-07
WO2011093524A1 (en) 2011-08-04
IL221146A (en) 2015-11-30
PL2528897T3 (pl) 2015-03-31
AU2011211306A1 (en) 2012-08-16
EP2528897B1 (en) 2014-10-15
CN102791690A (zh) 2012-11-21
EP2528897A1 (en) 2012-12-05
KR20120065268A (ko) 2012-06-20

Similar Documents

Publication Publication Date Title
HK1178523A1 (en) Di - substituted pyridine derivatives as anticancers
HRP20180672T1 (hr) Novi derivati piridina
HK1182594A1 (en) N3-substituted-n1-sulfonyl-5-fluoropyrimidinone derivatives n3--n1--5-
ZA201209117B (en) Tetrahydro-pyrido-pyrimidine derivatives
EP2524917A4 (en) CONDENSED PYRIDINE DERIVATIVES
EP2558094A4 (en) PYRIDONE DERIVATIVES
IL233001A0 (en) New iso-ergoline histories
GB2490849B (en) Di-aspirin derivatives
HK1174625A1 (en) Pyrrazolopyridine derivatives
HU1000243D0 (en) 8-hidroxy-quinoline derivatives
EP2592076A4 (en) SUBSTITUTED PYRIDINE COMPOUND
HK1206716A1 (en) Novel pyridine derivatives
ZA201209248B (en) Amido-tropane derivatives
IL220983A0 (en) 2-aldoximino-5-fluoropyrimidine derivatives